KIRSCH ARTHUR S sold $1.7M of LQDA (indirect holdings)

KIRSCH ARTHUR S sold 30,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $57.71 ($54.80–$60.22, $1.73M total) across 3 trades over 2026-06-01 to 2026-06-03.

Original reporting
SEC EDGAR · KIRSCH ARTHUR S
Published Jun 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest information is the disclosed sale size, price range, and post-sale share count (0), which may influence short-term sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or correlate with broader news, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales can be driven by diversification, tax, or pre-existing personal liquidity needs; the article provides no rationale, so the trading signal should be treated as sentiment-only.

Relevance 6/10Novelty 3/10Timing: filed June 3, 2026, covering sales from June 1 to June 3

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by a director via indirect holdings.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp (LQDA) disclosed an insider Form 4 showing director Kirs ch Arthur S sold 30,000 shares indirectly for about $1.73M.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 details a completed open-market sale across three trades at $54.80 to $60.22, with holdings after transaction at 0 shares. The disclosure does not include new company fundamentals, guidance, or regulatory/clinical developments.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the director ended with 0 shares and there is no stated 10b5-1 plan, some traders may interpret it as stronger-than-usual negative signaling, even if the filing is still typically low-signal.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Kirs ch Arthur S

    Director reporting an indirect open-market sale of 30,000 shares across three trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.